

UCC Library and UCC researchers have made this item openly available. Please [let us know](#) how this has helped you. Thanks!

Title	Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation
Author(s)	Twomey, Kate B.; Alston, Mark; An, Shi-Qi; O'Connell, Oisín J.; McCarthy, Yvonne; Swarbreck, David; Febrer, Melanie; Dow, J. Maxwell; Plant, Barry J.; Ryan, Robert P.
Publication date	2013
Original citation	Twomey KB, Alston M, An S-Q, O'Connell OJ, McCarthy Y, Swarbreck D, et al. (2013) Microbiota and Metabolite Profiling Reveal Specific Alterations in Bacterial Community Structure and Environment in the Cystic Fibrosis Airway during Exacerbation. PLoS ONE 8(12): e82432. doi:10.1371/journal.pone.0082432
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://dx.doi.org/10.1371/journal.pone.0082432 Access to the full text of the published version may require a subscription.
Rights	© 2015 Twomey et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited http://creativecommons.org/licenses/by/4.0/
Item downloaded from	http://hdl.handle.net/10468/2348

Downloaded on 2021-05-12T02:52:05Z

Table S1. Clinical data and treatment from CF and non-CF patients included in the study.

Patient no.	Age (year)	Sex	Clinical data patients			Treatment
			Known CFTR mutation ^a	BMI ^b	FEV ₁ ^c	AZ ^d
1	20	F	ΔF508	-	76	Y
2	34	M	ΔF508	29.1	53	Y
8	27	M	ΔF508	21.9	51	Y
10	53	F	ΔF508	21	44	Y
11	24	F	ΔF508	22.3	65	N
12	38	F	ΔF508	17.1	27	Y
13	29	F	ΔF508	16.5	64	Y
16	22	F	F50Y8	23.9	100	Y
17	21	F	ΔF508	20.1	98	N
19	19	F	ΔF508	-	29	Y
20	23	F	ΔF508	17.3	25	Y
21	31	F	ΔF508	20.8	48	Y
26	37	M	ΔF508	24.8	32	Y
27	20	M	ΔF508	-	77	Y
32	32	M	ΔF508	18.8	40	Y
33	27	M	ΔF508	21.9	60	Y
34	27	M	G551D	2.06	50	Y
35	31	M	ΔF508	20	20	Y
40	26	F	ΔF508	21.7	62	Y
43	24	F	ΔF508	34.4	93	Y
45	27	M	ΔF508	21.9	69	Y
46	28	M	ΔF508	27.1	95	N
47	28	M	ΔF508	27.1	95	N
48	26	F	ΔF508	24.5	63	Y
54	26	F	ΔF508	-	27	Y
55	20	F	ΔF508	18.5	24	N
57	26	F	ΔF508	23.1	25	Y
58	22	M	ΔF508	-	38	Y
59	37	F	ΔF508	18	24	Y

59	37	F	ΔF508	18	60	Y
62	19	M	ΔF508	-	-	Y
63	27	M	ΔF508	24.3	32	Y
70	19	F	ΔF508	20.2	70	Y
72	30	M	ΔF508	25.2	69	Y
74	23	M	ΔF508	23.4	87	N
75	23	M	ΔF508	23.4	87	N
76	39	M	ΔF508	19	33	-
78	24	F	ΔF508	19	49	Y
79	38	F	G551D	20.4	82	Y
80	23	F	ΔF508	18	41	Y
80	23	F	ΔF508	18	41	Y
83	43	F	ΔF508	17.9	24	N
84	29	F	ΔF508	22.5	47	Y
85	32	M	ΔF508	20.7	54	N
89	25	M	ΔF508	18	63	Y
92	27	M	ΔF508	19.7	67	Y
93	25	M	G551D	24	84	N
97	23	F	ΔF508	19	23	Y
99	26	M	ΔF508	19.1	27	Y
27		F	ΔF508	23.1	61	Y
101	37	M	ΔF508	23	70	Y
102	28	F	ΔF508	19.5	54	Y
103	29	F	ΔF508	20.5	70	-
104	31	M	ΔF508	21	85	N
105	30	M	ΔF508	21	44	Y
106	26	F	ΔF508	21.4	84	Y
107	21	M	ΔF508	22	97	Y
110	40	M	ΔF508	23	37	Y
111	28	F	ΔF508	19.5	62	N
113	26	M	ΔF508	24.3	55	Y
119	30	M	ΔF508	18.4	61	Y
121	20	F	ΔF508	20.4	64	-
123	25	F	F5Y08	18.5	100	Y
124	28	M	R560T	26.4	48	Y

126	22	F	ΔF508	15.8	30	N
128	28	M	ΔF508	24	29	Y
129	26	M	ΔF508	20	48	Y
129	26	M	ΔF508	20	48	Y
130	30	F	ΔF508	21.4	84	N
131	27	M	Non-CF	23.8	69	N
132	38	M	Non-CF	-	36	Y
133	25	F	Non-CF	-	77	-
134	57	F	Non-CF	-	55	-
135	53	F	ΔF508	21	44	Y
136	30	M	Non-CF	19.4	49	Y

a. Type of mutation detected in the CFTR, cystic fibrosis transmembrane conductance regulator;

b. BMI, body mass index;

c. FEV1, forced expiratory volume;

d. Patient is undergoing azithromycin (AZ) treatment where “Y” corresponds to Yes and N corresponds to “No”.